Trade Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals is a biotechnology company based in Dundee, Scotland, Luxor Hills, New Jersey, and the development of cancer drugs and treatments. Cyclacel was founded in 1996 by David Lane, Merlin Projects and Technology Cancer Research Campaign with the University of Dundee and the University of Glasgow. Major Shareholders include Goldman Sachs Group, Tang Capital Mangmen, Redmail Group And Wire Capital Management. company is developing a "drug-targeted mechanism" to help fight cancer, and other serious diseases, such as diabetes and HIV. Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral treatments that target various stages of control of the cell cycle for the treatment of cancer and other serious diseases. Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the P53 protein, founded the company in 1996. In 1999, Cyclacel was joined by pharmacist David Glover, a recognized leader in the split or cell mechanism, who discovered, among other cell cycle goals, mitochondrial kinasat, polo and aurora, enzymes that operate in the split phase of the cell cycle.